Hormone Resistant Prostate Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Clinical Trials

SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Condition:   Metastatic Castration-resistant Prostate Cancer Intervention:   Drug: SHR7390 Sponsor:   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 21, 2020 Category: Research Source Type: clinical trials

Radium Ra 223 Dichloride and Niraparib in Treating Patients With Hormone- Resistant Prostate Cancer Metastatic to the Bone
Conditions:   Prostate Carcinoma Metastatic to the Bone;   Stage IV Prostate Adenocarcinoma;   Hormone-refractory Prostate Cancer Interventions:   Drug: Niraparib;   Radiation: Radium Ra 223 Dichloride Sponsors:   Thomas Jefferson University;   Tesaro, Inc.;   Prostate Cancer Clinical Trials Consortium Not yet recruiting - verified March 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2017 Category: Research Source Type: clinical trials